Development of Enteric Coated Flurbiprofen Tablets using Opadry/acryl-eze System—A Technical Note

Hashmat, Durriya; Shoaib, Mohammad; Mehmood, Zafar; Bushra, Rabia; Yousuf, Rabia Ismail; Lakhani, Fahim

doi:10.1208/s12249-007-9005-9

Cited by 17 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stability studies 16,17 : For all the pharmaceutical dosage forms it is important to determine the stability of the dosage form. This will include storage at both normal and exaggerated temperature conditions, with the necessary extrapolations to ensure the product will, over its designed shelf life, provide medication for absorption at the same rate as when originally formulated.…”

Section: Experimental Methodsmentioning

confidence: 99%

Untitled

2013

IJPSR

View full text Add to dashboard Cite

The aim of this study was to develop a pH responsive enteric coated extended release pellets containing a model drug flurbiprofen, a nonsteroidal anti-inflammatory drug used for rheumatoid arthritis. The drug loaded pellets were prepared by using extrusion/ spheronization method. Core pellets were coated with polymer Eudragit RS30D in a coating pan to achieve a sustainable release for 12 hours. A ph responsive barrier coat of Eudragit L 100-55 was employed in a coating pan for abstaining release in acidic media. The drug excipient mixtures were subjected to pre-formulation studies. The pellets were subjected to physicochemical studies, in-vitro drug release, Kinetic studies and stability studies. FTIR studies shown there was no interaction between drug and polymers. The physicochemical properties of pellets were found within the limits. The drug release from the optimized formulations was extended for a period of 12 hrs i.e. first 2 hrs no drug release was observed and gradually drug release was increased up to 12 hrs. From the above results, achievement of site specific release to lower part of gastrointestinal tract might be due to Eudragit L 100-55 stability in acidic pH. The prepared pellets apart from fulfilling all official and other specifications, exhibited good extended release of Flurbiprofen. The optimized formulations were subjected to stability studies and shown there were no significant changes in drug content, physicochemical parameters and release pattern. In conclusion, development of Eudragit RS30D-Eudragit L 100-55 was novel and good approach to achieve the site specific release of drug to colon.

show abstract

Section: Experimental Methodsmentioning

confidence: 99%

Untitled

2013

IJPSR

View full text Add to dashboard Cite

show abstract

“…All the formulations were prepared with similar blending time and compaction conditions. [2][3][4][5][6][7] The composition of the core tablets is shown in Table. 1.…”

Section: Preparation Of Core Tabletsmentioning

confidence: 99%

Development of Extended Release Formulations of Ilaprazole Tablets

Divya

Sreekanth

Satyavati

2019

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Extended release products are designed to release their medication in a controlled manner at a predetermined rate, duration, and location to achieve and maintain optimum therapeutic blood levels of a drug. The objective of the study is to formulate and evaluate Ilaprazole Controlled release tablets comparable to the innovator product. F1-F9 formulations were prepared using varying concentrations of super disintegrates like Crospovidone, Croscarmellose sodium and Sodium starch glycolate in different concentrations. Based on the hardness, friability, weight variation, drug content, F6 formulation was found to be optimised. The selected F6 formulation was sub coated with HPMC P 50 and followed by enteric coating with Acryl-EZE-80 (Eudragit L100-55). 3 formulations (F10-F12) were prepared by using coating. Among the three formulations, F11 formulation was found to be best. FTIR studies were carried out to find out drug and excipient compatibility studies, the studies revealed that there were no interactions. DSC studies also carried out to demonstrate any changes in physical forms of the drug molecule. Keywords: Ilaprazole, Extended release tablets, Crospovidone, Croscarmellose sodium, Sodium starch glycolate, HPMC P 50, Acryl-EZE-80.

show abstract

“…Patel (2015) [8] showed how statistical process control could be used to control weight uniformity of tablets. Hashmat et al (2008) [9], used shewhart quality control plots for tablet hardness, tablet thickness and weight variation of tablets. Brochmann and medin (2006) [10] considered the variation in weight and variation in percent composition as two sources of variability affecting the drug dosage in tablet.…”

Section: Introductionmentioning

confidence: 99%

Capability Analysis and use of Acceptance and Control Charts in the 6-Sigma in Pharmaceutical Industries Case Study: Behestan Tolid Pharmaceutical Co

Mehdi¹,

Asl²

2016

IJAIS

View full text Add to dashboard Cite

Different Industries use the acceptance charts to assess if the process could meet customer specified requirements because the acceptance charts are competent tool to answer the critical question that's to see if the process average stays between acceptable levels so the final product meets the customer specification levels. Also process capability determines that if the manufacturer could meet customer's requirements or should improve its process by reducing the process variation and fitting it's mean. What is discussed in this paper, is the use of the mentioned charts in 6-Sigma applications and how the capability analysis results help to know the status of production specifications. A case-study as an example is included to clarify the acceptance chart concepts.

show abstract

Development of Enteric Coated Flurbiprofen Tablets using Opadry/acryl-eze System—A Technical Note

Cited by 17 publications

References 7 publications

Untitled

Untitled

Development of Extended Release Formulations of Ilaprazole Tablets

Capability Analysis and use of Acceptance and Control Charts in the 6-Sigma in Pharmaceutical Industries Case Study: Behestan Tolid Pharmaceutical Co

Contact Info

Product

Resources

About